Literature DB >> 1664344

Antipoliomyelitis immunity status among a population that was regularly vaccinated 11-12 years before.

E Bellelli1, M L Tanzi, V Bocelli, U Bracchi, P Affanni.   

Abstract

A study of poliomyelitis neutralizing antibodies was carried out on 165 samples of blood serum drawn from subjects aged 14-15 years who had completed vaccination with OPV 11 or 12 years ago. Two different methods of incubation of the serum-virus mixtures (1 hour at 37 degrees C; 6 hours at 37 degrees C and then 18 hours at 4 degrees C, respectively) and two different cell lines (RC-37 and Hep-2) for the inoculation of these mixtures were employed. The results were also evaluated in relation to different initial dilutions of the sera (from 1:4 to 1:1). With the 1:4 initial serum dilution the highest frequencies of sero-negativity were observed utilizing the short incubation time and inoculation in Hep-2 (42% for polio 1, 10% for polio 2, 32% for polio 3). These frequencies diminish significantly utilizing the RC-37 cell line and the long incubation respectively. Under all the experimental conditions the results were better when the 1:2 initial serum dilutions were employed and even better when undiluted sera were used. Neutralizing antibodies against the 3 types of poliovirus were detected in the undiluted sera of all the subjects utilizing the long incubation and inoculation in either the RC-37 or the Hep-2 cell lines. In three subjects lacking detectable antibodies at the 1:4 dilution of the sera, the administration of a dose of IPV produced after 5-7 days a high response which remained almost unchanged 30 days later.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1664344     DOI: 10.1007/bf00218669

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  28 in total

1.  Present status of the problem of vaccination against poliomyelitis.

Authors:  J E SALK
Journal:  Am J Public Health Nations Health       Date:  1955-03

2.  Viremia Following the Administration of Live Poliovirus Vaccines.

Authors:  H W McKay; A R Fodor; U P Kokko
Journal:  Am J Public Health Nations Health       Date:  1963-02

3.  Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series.

Authors:  J W Bass; S B Halstead; G W Fischer; J K Podgore; R A Wiebe
Journal:  JAMA       Date:  1978-05-26       Impact factor: 56.272

4.  Prevalence of antibody to poliovirus.

Authors:  M S Rooney; P V Coyle; J H Connolly
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-13

5.  Antibody titers to polioviruses in patients ten years after immunization with sabin vaccine.

Authors:  D Y Sanders; H G Cramblett
Journal:  J Pediatr       Date:  1974-03       Impact factor: 4.406

6.  Characterization of strains of type 3 poliovirus by oligonucleotide mapping.

Authors:  P D Minor
Journal:  J Gen Virol       Date:  1982-04       Impact factor: 3.891

7.  [Biological and biochemical characteristics of poliovirus strains isolated after the introduction of oral antipoliomyelitis vaccine].

Authors:  M L Profeta; I F Pazardjiklian
Journal:  Ann Sclavo       Date:  1982 Sep-Oct

8.  Inadequate serological surveys for immunity to poliomyelitis. Inadequate indicators of immune status of communities using oral poliovirus vaccine and inadequate guides to vaccination policy.

Authors:  A B Sabin
Journal:  Med J Aust       Date:  1983-02-05       Impact factor: 7.738

9.  Multiple genetic changes can occur in the oral poliovaccines upon replication in humans.

Authors:  O M Kew; B K Nottay; M H Hatch; J H Nakano; J F Obijeski
Journal:  J Gen Virol       Date:  1981-10       Impact factor: 3.891

Review 10.  Eradication of poliomyelitis in the United States. III. Poliovaccines--practical considerations.

Authors:  D Salk
Journal:  Rev Infect Dis       Date:  1980 Mar-Apr
View more
  2 in total

1.  Antipoliomyelitis neutralizing antibodies in maternal and neonatal serum.

Authors:  M L Tanzi; P Colotto; M Vignali; P Affanni; U Bracchi; E Bellelli
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

2.  Persistence of immunity to poliomyelitis among a southern population that received four doses of OPV 5 to over 15 years before.

Authors:  M Triassi; G Ribera; L Barruffo; S Barbone; E Medda; M E Grandolfo
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.